A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

被引:20
|
作者
Matsumoto, Hiroshi [1 ]
Kawazoe, Akihito [1 ]
Shimada, Kaoru [2 ]
Fukuoka, Shota [1 ]
Kuboki, Yasutoshi [1 ]
Bando, Hideaki [1 ]
Kojima, Takashi [1 ]
Ohtsu, Atsushi [1 ]
Yoshino, Takayuki [1 ]
Doi, Toshihiko [1 ]
Shitara, Kohei [1 ]
机构
[1] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan
[2] Natl Canc Ctr Hosp East, Dept Diagnost Radiol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan
来源
BMC CANCER | 2018年 / 18卷
关键词
Gastric cancer; Ascites; Progression-free survival; Paclitaxel; Ramucirumab; PHASE-III; PERITONEAL METASTASIS; PROGNOSTIC MODEL; CHEMOTHERAPY; CISPLATIN; ADENOCARCINOMA; TRIAL; SURVIVAL; S-1;
D O I
10.1186/s12885-018-4057-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ramucirumab has recently proved to be effective for advanced or recurrent gastric cancer (AGC). Ascites and peritoneal metastasis are among the most common complications of AGC. However, there are few data on the safety and efficacy of paclitaxel plus ramucirumab in patients with AGC with ascites. The purpose of this retrospective study was to evaluate the safety and efficacy of paclitaxel plus ramucirumab in patients with AGC with ascites. Methods: We retrospectively evaluated the safety and efficacy of paclitaxel plus ramucirumab in patients with AGC with ascites in comparison with patients without ascites in a single institution from June 2015 to May 2016. The median progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method, and differences evaluated using the Log-lank test. The differences in baseline characteristics and response rates of each ascites group were calculated for homogeneity by chi-square tests and for trends by Fisher's exact test. Results: Eighty-three patients were analyzed in this study. Ascites was detected in 40 patients, 26 patients (31%) had small to moderate ascites and 14 (17%) had massive ascites. The proportion of patients who started with a reduced dose of paclitaxel was higher for patients with massive ascites than others. The frequencies of any grade 3 or 4 hematological toxicity were 51% in patients without ascites, 77% in patients with small to moderate ascites, and 71% in patients with massive ascites. The frequencies of common ramucirumab-related adverse events were also not significantly different among ascites groups, however one patient had a tumor hemorrhage, and one patient had a gastrointestinal perforation. PFS and OS were shorter in patients with massive ascites than in patients with small or moderate ascites or patients without ascites. Conclusions: The use of paclitaxel and ramucirumab in patients with AGC with large amounts of ascites was tolerable with adequate dose modification. However, we should pay attention to the risks of ramucirumab-related toxicity in patients with bleeding tumors or intestinal stenosis.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients
    Kobayashi, Michiya
    Sakamoto, Junichi
    Namikawa, Tsutomu
    Okamoto, Ken
    Okabayashi, Takehiro
    Ichikawa, Kengo
    Araki, Keijiro
    WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (09) : 1412 - 1415
  • [32] Paclitaxel plus ramucirumab combination therapy as second-line therapy in elderly patients with metastatic advanced gastric cancer: A single-center retrospective study
    Kashiwada, A.
    Nishioka, A.
    Aragane, N.
    Kimura, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] Ratio of neutrophil to lymphocytes is useful to predict the prognosis of patients with paclitaxel plus ramucirumab treatment for unresectable advanced or recurrent of gastric or gastroesophageal junction cancer
    Miura, Ko
    Tozawa, Katsuyuki
    Hara, Ken
    Kitayama, Yoshitaka
    Nakamura, Kumiko
    Ogawa, Tomohiro
    Kondo, Takashi
    Kono, Tomoaki
    Tomita, Toshihiko
    Oshima, Tadayuki
    Fukui, Hirokazu
    Watari, Jiro
    Miwa, Hiroto
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 367 - 367
  • [34] Evaluation of the safety of ramucirumab in Japanese patients with advanced gastric cancer
    Iwai, M.
    Ito, D.
    Asano, H.
    Adachi, S.
    Okada, K.
    Kimura, M.
    Usami, E.
    Matsuo, K.
    Yoshimura, T.
    Teramachi, H.
    PHARMAZIE, 2018, 73 (05): : 309 - 312
  • [35] Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study
    Xue Wang
    Jinxiang Huang
    He Huang
    Yang Liu
    Chao Ji
    Jian Liu
    Investigational New Drugs, 2023, 41 : 579 - 586
  • [36] Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study
    Wang, Xue
    Huang, Jinxiang
    Huang, He
    Liu, Yang
    Ji, Chao
    Liu, Jian
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (4) : 579 - 586
  • [37] Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study
    Li Jiang
    Jie Zhu
    Xue Chen
    Yi Wang
    Lei Wu
    Gang Wan
    Yongtao Han
    Xuefeng Leng
    Lin Peng
    Qifeng Wang
    Radiation Oncology, 17
  • [38] Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study
    Jiang, Li
    Zhu, Jie
    Chen, Xue
    Wang, Yi
    Wu, Lei
    Wan, Gang
    Han, Yongtao
    Leng, Xuefeng
    Peng, Lin
    Wang, Qifeng
    RADIATION ONCOLOGY, 2022, 17 (01)
  • [39] Safety, Feasibility, and Efficacy of Capecitabine Maintenance in Patients With Advanced Gastric Cancer: A Retrospective Study
    Eren, Orhan Onder
    Ozturk, Mehmet Akif
    Sonmez, Ozlem Uysal
    Oyan, Basak
    AMERICAN JOURNAL OF THERAPEUTICS, 2016, 23 (06) : E1493 - E1497
  • [40] Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer
    Sadayuki Kawai
    Naoki Fukuda
    Shun Yamamoto
    Seiichiro Mitani
    Katsuhiro Omae
    Takeru Wakatsuki
    Ken Kato
    Shigenori Kadowaki
    Daisuke Takahari
    Narikazu Boku
    Kei Muro
    Nozomu Machida
    BMC Cancer, 20